HCV Advocate Logo HCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 
News Review

Back to News Review

HEPATITIS JOURNAL REVIEW:
A Bi-Monthly Publication of the Hepatitis Support Project

August 25 , 2009
Volume 6, Issue 8


Liz Highleyman

To download pdf version click here


In This Issue:

 

Genetic Variation Predicts Response
A human genetic variation, or polymorphism, helps explain differences in response to interferon-based therapy for hepatitis C, according to a study reported in the August 6 advance online edition of Nature.  D. Ge and colleagues analyzed genetic material from 1,671 participants in the IDEAL trial, which comparing pegylated interferon alfa-2a (Pegasys) against two doses of pegylated interferon alfa-2b (PegIntron), all with weight-adjusted ribavirin.

The researchers found that a variation (designated rs12979860) in a single nucleotide at a specific position on chromosome 19, near the IL28B gene – which encodes interferon-lambda-3 – was associated with nearly a three-fold increase in treatment response rate.  Patients with the CC genotype had a sustained virological response (SVR) rate of about 80%, compared with about 30% for those with the CT or TT genotypes.  The polymorphism was associated with improved treatment response in people of all racial/ethnic groups, but the likelihood of having the mutation varied.  People of East Asian descent were most likely to carry the favorable pattern, followed by European-Americans, Hispanics, and African-Americans.  The researchers concluded that the rs12979860 polymorphism "explains approximately half of the difference in response rates between African-Americans and patients of European ancestry."


Back to top


Statins Active Against HCV
Statin drugs (HMG CoA reductase inhibitors) demonstrated anti-HCV activity themselves and increased the antiviral activity of interferon and directly-targeted agents in a laboratory study reported in the July 2009 issue of Hepatology.  L. Delang and colleagues assessed the activity of various statins against HCV replicons in cell cultures.  Among the five statins tested, mevastatin (not approved) and simvastatin (Zocor) exhibited the strongest in vitro activity.  Lovastatin (Mevacor) and fluvastatin (Lescol) had moderate antiviral activity, while pravastatin (Pravachol) was "devoid of an antiviral effect."

When the researchers combined the statins with interferon-alfa or HCV polymerase and protease inhibitors, they observed additive antiviral activity.  While neither statins alone nor any of the tested anti-HCV agents alone completely cleared HCV from cell cultures, a combination of HCV polymerase or protease inhibitors plus mevastatin or simvastatin produced efficient clearance.  Furthermore, adding mevastatin inhibited the emergence of HCV replicons with resistance to the investigational polymerase inhibitor HCV-796 (no longer in development).  "A combination of specific HCV inhibitors with statins may result in a more profound antiviral effect and may delay or prevent the development of resistance to such inhibitors," they concluded.


Back to top


Steatosis
Two recent studies looked at the natural history and progression of steatosis, or fat accumulation in liver cells, among people with hepatitis C.  In the first study, reported in the June issue of Hepatology, A. Lok and colleagues assessed the evolution of steatosis among participants in the HALT-C trial, which evaluated long-term pegylated interferon monotherapy as a maintenance regimen to slow liver disease progression in patients without sustained response to combination therapy.  Out of 1,000 total trial participants (more than 90% with HCV genotype 1), 892 had at least one follow-up liver biopsy and 699 had their last biopsy 3.5 years after randomization to the maintenance therapy or no further treatment arms. 

At study entry, 39% of patients had cirrhosis and 61% had bridging fibrosis.  With regard to steatosis, 8% had a score of 0 (no steatosis), 41% a score of 1 (mild), 31% a score of 2 (moderate), and 10% a score of 3 or 4 (advanced).  The mean steatosis score decreased in follow-up biopsies from patients in both the interferon maintenance and no further treatment arms.  About one-third experienced a decrease in steatosis score of at least one point.  Patients who experienced decreasing steatosis had worse metabolic parameters at enrollment, improved metabolic parameters during follow-up, worsening liver disease during follow-up (cirrhosis, esophageal varices, or deteriorating liver function), and were more likely to reduce their consumption of alcohol.  "Serial biopsies demonstrated that in patients with [chronic hepatitis C], steatosis recedes during progression from advanced fibrosis to cirrhosis," the researchers concluded.  "Decreased alcohol intake and improved metabolic parameters are associated with a decline in steatosis and may modulate hepatitis C progression." 

In the second study, published in the July 2009 Journal of Viral Hepatitis, T. J. Cross and colleagues performed a retrospective analysis of 112 chronic hepatitis C patients who underwent two liver biopsies separated by a median of 50 months.  Participants were not treated for hepatitis C (i.e., they had mild fibrosis, declined therapy, or had contraindicating conditions).  On the first liver biopsy, 54% had stage S0 steatosis (less than 5% of liver cells affected), 30% had stage S1 (5% to 33% of cells), 11% had stage S2 (33% to 66% of cells), and 5% had stage S3 (more than 66% of cells).  Presence of steatosis was associated with HCV genotype 3. 

About one-fifth (21%) exhibited fibrosis progression on the second biopsy (increase of at least one Ishak stage).  In a multivariate analysis, baseline steatosis was the only significant predictor of fibrosis progression, with an odds ratio of 14.3.  "The finding that steatosis was significantly associated with fibrosis progression indicates that, independent of baseline fibrosis stage, patients should be considered for antiviral treatment if steatosis is present," the researchers recommended.


Back to top


Cardiovascular Risk
People with chronic hepatitis C are more likely than those without to develop cardiovascular disease, according to a study reported in the July 15 Clinical Infectious Diseases.  A. Butt and colleagues looked at the link between HCV infection and coronary artery disease among 82,083 HCV positive and 89,582 HCV negative patients receiving care at Veterans Affairs medical facilities.

In a multivariate analysis, HCV positive patients were about a 25% more likely than HCV negative patients to have coronary artery disease.  This was the case even though people without HCV were older on average, had higher blood lipid (cholesterol and triglyceride) levels, and were more likely to have high blood pressure and diabetes – all established cardiovascular risk factors.  “Despite a favorable risk profile, HCV infection is associated with a higher risk of coronary artery disease after adjustment for traditional risk factors,” the investigators concluded.  They suggested that the elevated risk might be due to ongoing inflammation and immune activation related to chronic viral infection. 


Back to top


HCV Transmission among HIV Positive Gay Men
Several years ago, European researchers began reporting outbreaks of apparently sexually transmitted acute HCV infection among HIV positive men who have sex with men (MSM) in urban centers.  In the July 31 issue of AIDS, A. Urbanus and colleagues published an update on the expanding epidemic in Amsterdam.  The investigators studied the prevalence of and risk factors for HCV infection among 3,125 clients – including 689 MSM – at a large sexually transmitted disease clinic during 2007-2008.  Participants were interviewed and screened for HIV and HCV antibodies and tested for HCV RNA if antibody positive. 

Just 2 of 532 (0.4%) HIV negative MSM were found to be infected with HCV, compared with 28 of 157 (17.8%) HIV positive MSM.  Among HIV positive MSM, HCV prevalence increased from 14.6% to 20.9% over the study period.  One-quarter (7 of 28) of the coinfected men had acute HCV infection acquired within the prior six months.  HIV infection, injection drug use (reported by 5 of 28 coinfected MSM, or 17.9%), fisting, and use of the club drug GHB were significantly risk factors for HCV infection. 

Genetic analysis revealed a high degree of clustering of HCV strains with networks of gay and bisexual men.  The researchers concluded that, "Regardless of [injection drug use], rough sexual techniques and use of recreational drugs were associated with HCV infection." They recommended that, "Targeted prevention, like raising awareness and routine testing, is needed to stop the further spread [of HCV] among HIV infected MSM, and to prevent possible spillover to HIV negative MSM."


Back to top


Back to News Review



About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Resources en Espaņol | Home

Hepatitus C Support Project
(C) 2009. Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets